Dermatology clinical trials are on the rise, especially in the indications of acne, atopic dermatitis, and psoriatic arthritis.1 Over the course of the past three years, the number of dermatology clinical trials has increased over 40%,2 despite an overall decline in clinical trials for all therapeutic areas.
With dermatology trials in an upswing, there is increased demand for volunteers, especially for the indications actively recruiting in greater numbers. Analyzing previous studies for the metrics-driven data attained can be a tremendous foundation for new studies.
In addition to the metrics, changes in the way in which potential recruits seek out and consume media are an important factor in the success, or failure, of dermatology recruitment. Additionally, more and more dermatological studies are seeking specialized populations to satisfy their challenging protocols. A solid understanding of how and where to reach these populations, and gain their trust, is vital to recruitment efforts.
With the expansion of global trials, especially in later phase studies, it is critical to have a comprehensive understanding of the nuances of each geographic area, from media reach and cultural mores, to economic conditions. And with this expanded reach, it is imperative that solid relationships are developed and maintained with sites, to help ensure transparent communication and steady enrollment worldwide.
In a recent article published by International Clinical Trials, my colleague Senior Vice President Darcee Strube and I discuss these considerations that both sponsors and CROs must consider in order to meet this new demand for recruitment in an ever-expanding field of dermatology clinical trials. To learn more about our discussion, please read the ICT article, “Evolving Trends in Patient Recruitment for Dermatology Clinical Trials.”
Citeline Pharma R&D Annual Review 2014 & 2015, and Pharmaprojects Pharma R&D Annual Review 2016. Citeline.